• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu

News

Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma

1 de May de 2023
Front Immunol. 2023 Apr 12;14:1158105. doi: 10.3389/fimmu.2023.1158105.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-05-01 10:00:002023-05-01 10:00:00Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma

Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients

27 de April de 2023
Haematologica. 2023 Oct 1;108(10):2753-2763. doi: 10.3324/haematol.2022.282490.ABSTRACTIn…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-04-27 10:00:002023-04-27 10:00:00Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients

CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?

24 de April de 2023
Front Neurol. 2023 Apr 6;14:1144414. doi: 10.3389/fneur.2023.1144414.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-04-24 10:00:002023-04-24 10:00:00CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?

Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era

19 de April de 2023
Bone Marrow Transplant. 2023 Jun;58(6):738. doi: 10.1038/s41409-023-01967-9.NO…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-04-19 10:00:002023-04-19 10:00:00Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era

Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party

18 de April de 2023
J Immunother Cancer. 2023 Apr;11(4):e006406. doi: 10.1136/jitc-2022-006406.ABSTRACTWe…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-04-18 10:00:002023-04-18 10:00:00Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party

Feasibility of extended ultrasound examination of the fetal brain between 24 and 37 weeks’ gestation in low-risk pregnancies

17 de April de 2023
J Perinat Med. 2023 Apr 18;51(6):815-822. doi: 10.1515/jpm-2022-0605.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-04-17 10:00:002023-04-17 10:00:00Feasibility of extended ultrasound examination of the fetal brain between 24 and 37 weeks’ gestation in low-risk pregnancies

Editor’s Note: Dual Targeting of the Akt/mTOR Signaling Pathway Inhibits Castration-Resistant Prostate Cancer in a Genetically Engineered Mouse Model

4 de April de 2023
Cancer Res. 2023 Apr 4;83(7):1160. doi: 10.1158/0008-5472.CAN-23-0516.NO…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-04-04 10:00:002023-04-04 10:00:00Editor’s Note: Dual Targeting of the Akt/mTOR Signaling Pathway Inhibits Castration-Resistant Prostate Cancer in a Genetically Engineered Mouse Model

Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma

31 de March de 2023
Clin Cancer Res. 2023 May 15;29(10):1894-1905. doi: 10.1158/1078-0432.CCR-22-3136.ABSTRACTPURPOSE:…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-03-31 10:00:002023-03-31 10:00:00Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma

Reduced Graphene Oxide Aerogels Cartridges for Solid Phase Extraction of Benzotriazoles

29 de March de 2023
Materials (Basel). 2023 Mar 22;16(6):2519. doi: 10.3390/ma16062519.ABSTRACTUV-benzotriazoles…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-03-29 10:00:002023-03-29 10:00:00Reduced Graphene Oxide Aerogels Cartridges for Solid Phase Extraction of Benzotriazoles

Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy

27 de March de 2023
Bone Marrow Transplant. 2023 Jun;58(6):696-700. doi: 10.1038/s41409-023-01958-w.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-03-27 10:00:002023-03-27 10:00:00Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy

Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV)

25 de March de 2023
Bone Marrow Transplant. 2023 Jun;58(6):727-728. doi: 10.1038/s41409-023-01962-0.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-03-25 10:00:002023-03-25 10:00:00Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV)

Excessive transcription-replication conflicts are a vulnerability of BRCA1-mutant cancers

17 de March de 2023
Nucleic Acids Res. 2023 May 22;51(9):4341-4362. doi: 10.1093/nar/gkad172.ABSTRACTBRCA1…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-03-17 10:00:002023-03-17 10:00:00Excessive transcription-replication conflicts are a vulnerability of BRCA1-mutant cancers
Page 27 of 88«‹2526272829›»

Filter by categories

  • Alemany’s & Piulats’s lab (135)
  • Antolin's lab (36)
  • Aytes's Lab (25)
  • Belver's Lab (25)
  • Casanovas's Lab (77)
  • Martínez-Balibrea's Lab (43)
  • Menendez's Lab (121)
  • Molleví's Lab (35)
  • Pujana's Lab (112)
  • Sin categoría (12)
  • Sureda's & Farre's Lab (319)
  • Viñals's lab (114)

Twitter

Tweets by ProcureICO
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}